SOPHiA GENETICS closes USD57.5m Public Offering of Ordinary Shares

Niederer Kraft Frey advised SOPHiA GENETICS in this public offering on Nasdaq.

SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, closed its underwritten public offering with total gross proceeds of USD57.5m, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company.

As a result of strong investor demand, the offering was oversubscribed, and the underwriters fully exercised their option to purchase additional ordinary shares at the public offering price, less the underwriting discounts and commissions. All of the ordinary shares were sold by the Company.

TD Cowen acted as the lead book-running manager for the offering. Guggenheim Securities acted as book-running manager, and BTIG and Craig-Hallum acted as lead managers for the offering.

The NKF team was led by Corporate/M&A/Transactions partner Jacques Bonvin, working with partner Deirdre Ni Annrachain (Transactions/Capital Markets), associate Boris Catzeflis (Corporate/ M&A) and counsel Marc Vogelsang (Tax).